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Abstract
Introduction: End-stage renal disease (ESRD) is associated with increased
infectious susceptibility and with reduced vaccine responses consistent with
compromised humoral immunity. Whether the compromised humoral immunity
is due to reduced antibody diversity (reduced somatic hypermutation [SHM]) or
altered germinal center (GC) dynamics is not known. The GC-derived chemokine
CXCL13 as well as peripheral T follicular helper cells (pTFH) reflect GC dynamics,
but have, similar to SHM, never been characterized in relation to ESRD.
Methods: SerumCXCL 13was determined by ELISA. PTFHwere flow-cytometrically
defined as CD4þ CD45RA CCR7þ CXCR5þ lymphocytes. Apoptotic lymphocyte
subsets were in addition annexin Vþ. SHM was determined, by next-generation
sequencing and bioinformatics, as nucleotide mutations within the IgG VH
(comprising the important antigen-binding domains of IgG, CDR1, and CDR2).
Results: Elevated CXCL13 levels characterized ESRD (n¼ 19; [median] 90 pg/ml,
P< 0.01) (controls, n¼ 18; 62 pg/ml). ESRD pTFH frequencies (n¼ 19; 11.6% [of
CD4þ memory T cells], P< 0.02, Bonferroni corrected) (controls, n¼ 22;
14.9%) and concentrations (n¼ 19; 0.03 109/L, P< 0.02) (controls, n¼ 22;
0.07 109/L) were reduced. ESRD pTFH were more apoptotic (n¼ 9; 25.7%,
P¼ 0.04) (controls, n¼ 10; 15.9%). SHM did not discriminate between ESRD
(n¼ 10; 7.4%, P¼ 0.21) and controls (n¼ 10; 8.4%).
Conclusions: Elevated CXCL13 levels, reduced pTFH levels, and increased pTFH
apoptosis suggest that perturbed GC dynamics, and not reduced antibody
diversity, underlie the diminished vaccine responses and the compromised
humoral immunity in ESRD. However, largely preserved SHM provides a rationale
for pursuing vaccination in relation to ESRD.
Introduction
End-stage renal disease (ESRD) is characterized by attenuated
responses to a range of vaccines [1–4] and an increased
propensity for infections with encapsulated bacteria [5, 6]
consistent with compromised humoral immunity. Peripheral
CXCR5þ T cells, comprising 20–25% of the CD4þ central
memory T cell pool, are important for antibody-recall
responses [7]. CXCR5 is the receptor for the germinal center
(GC)-derived chemokine CXCL13. Following activation,
peripheral CXCR5þ T follicular helper cells (pTFH) support
plasma cell differentiation and Ig production [8], and pTFH
differentiation reflect GC function [9] In the GC, CXCL13
facilitates the interaction between CXCR5þ T and CXCR5þ B
cells, resulting in the production of antigen-specific anti-
bodies [10]. Progressively elevatedCXCL13 levels relate to the
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antibody dysfunction accompanying progressive HIV infec-
tion [11] and correlate with disease severity and auto-
antibody production in SLE [12]. The B-cell compartment
can be (severely) affected in ESRD [13]. However, somatic
hypermutation (SHM) may be more predictive of infectious
susceptibility than reduced B-cell numbers [14]. It is,
therefore, relevant to access SHM in ESRD patients, since
decreased SHM will influence the range of microbes their
humoral immune system can effectively engage. SHM entails
the random insertion of nucleotides into the variable regions
of heavy and light chain immunoglobulin genes [15] thereby
ensuring additional antibody diversity. In the GC, SHM is
followed by antigen mediated selection of high affinity
antibodies [16] ensuring the best antibody fit to the eliciting
antigen(s). Due to the aberrant vaccination kinetics and the
increased susceptibility to infections with encapsulated
bacteria, we hypothesized, that ESRD is accompanied by
deviating CXCL13 and pTFH characteristics as well as
reduced SHM.
Materials and Methods
Preceding inclusion, participants received oral and written
information and written consent was subsequently obtained
from all participants.
ESRD patients and controls
ESRD patients were maintained on hemodialysis (HD) for at
least 6 months (three times/week) prior to inclusion (n¼ 19,
protocol-id: S-20110085, clinical and para-clinical charac-
teristics, Table 1). ESRD patients with acute illness or in
immunosuppressive therapy were excluded.
Among age- and gender-matched controls (n¼ 22,
protocol-id: S-20110085, clinical and para-clinical character-
istics, Table 1), pregnancy, infections, auto-immunity,
malignancy and chronicmedicationwere causes for exclusion.
Blood collection
Among controls, blood was collected by venipuncture by
applying gentle aspiration. In the ESRD group, blood was
drawn after canulation of the vascular access but prior to
dialysis. In 11 ESRD patients, serum samples were also
obtained immediately after dialysis. For the ESRD and the
control group, leucocyte, neutrophil and monocyte counts
were determined by the Sysmex XE-1800i automated blood
cell counter.
T and B cells
Absolute numbers of CD3þ, CD4þ, and CD8þ T cells as well
as CD19þ B cells were determined by flow- cytometry.
Flow-cytometric characterization of pTFH
Flow-cytometrically, pTFHwere identified as CD4þCD45RA
CCR7þCXCR5þ lymphocytes. Percentages of apoptoticCD4þ
CD45RA CXCR5 memory T cells and apoptotic CXCR5þ
pTFH were determined by additional positivity for annexin V.
Table 1. Clinical and para-clinical characteristics of ESRD patients and age/gender-matched controls.
Controls (n¼ 22) ESRD (n¼ 19) P-value
Median (min–max) Median (min–max) Con. vs. ESRD
Age (years) 54.6 (33.3–67.2) 62.2 (30.3–82.1) 0.37
Women (%) (45.5) (52.6) 0.65
Creatinine (mmol/L) 70 (52–100) 818 (501–1,375) <0.01
Blood urea nitrogen (mmol/L) 5.2 (3.5–8.7) 21.8 (7.1–29.9) <0.01
CRP (<10.0mg/L) 0.8 (0.3–8.2) 3.2 (0.5–50.8) <0.01
Albumin (g/L) 47 (41–51) 39 (3545) <0.01
PTH (mmol/L) 4.6 (2.4–9.2) 38.7 (7.4–257.0) <0.01
Leukocytes (109/L) 6.3 (3.7–10.6) 6.6 (3.6–15.4) 0.92
Neutrophils (109/L) 3.6 (1.7–7.3) 4.0 (1.813.4) 0.41
Monocytes (109/L) 0.5 (0.3–0.9) 0.5 (0.3–0.8) 0.75
Lymphocytes (13/L) 1.9 (0.8–3.1) 1.1 (0.9–1.9) <0.01
CD3þ (109/L) 1.3 (0.6–2.5) 0.9 (0.2–1.2) <0.01
CD4þ (109/L) 1.0 (0.4–1.9) 0.5 (0.2–1.0) <0.01
CD8þ (109/L) 0.4 (0.1–1.1) 0.3 (0.0–0.5) 0.26
CD19þ (109/L) 0.2 (0.1–0.4) 0.1 (0.0–1.3) <0.01
CD16þ CD56þ (109/L) 0.2 (0.1–0.7) 0.2 (0.0–0.6) <0.05
CD4þ/CD8þ 2.5 (1.1–9.8) 1.6 (0.6–6.0) 0.09
CD4þ CD45RA T cells (% CD4þ) 42.3 (20.5–76.1) 64.2 (36.6–82.6) <0.01
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Absolute pTFH numbers were calculated by multiplying their
frequencies with the total CD4þ count.
Relative CXCR5 expression (delta [D] median fluores-
cence intensity [MFI]) was determined as: (MFI)
(CD4þCD45RACCR7þ CXCR5þ subset) FITC chan-
nel—MFI (CD4þCD45RA CCR7þ CXCR5 subset)
FITC channel. The gating procedure was as follows: the
initial gate was set on CD4 followed by a gate on CD45RA
(as shown in Fig. 1a) followed by a gate on CCR7 followed
by determination of CXCR5þ MFI respectively back-
ground MFI (FITC channel) of CXCR5 central memory
T cells.
CXCL-13 ELISA
Measurement of serum CXCL13 levels was performed with
an enzyme-linked immunosorbent assay (ELISA) (Quan-
tikine Human CXCL13 ⁄BLC ⁄BCA-1 Immunoassay; R&D
Systems GmbH, Wiesbaden, Germany) using the manu-
facturer’s instructions. Samples were run in duplicate.
PCR and next-generation sequencing of the IgG
VH gene
Mononuclear cells were thawed, andmRNA was isolated from
3 to 6 106 cells using MagAttract Direct mRNA M48 kit
(Qiagen, Hilden, Germany) on a KingFisher (Thermo
LabSystems, Waltham, Massachusetts, USA). Synthesis of
cDNAwasperformed in1XPCRbuffer II, 5mMMgCl2, 1U/ml
RNnase inhibitor, 0.1mM dNTP mix, 2.5mM IgG specific
primer (50-GCCTGAGTTCCACGACACC), 2.5U/ml MulV
reverse transcriptase (all from Life Technologies, Carlsbad,
USA), and 51ml of mRNA in a total volume of 100ml. The
reaction mixtures were incubated at 428C for 30min, and at
948C for 5min. The region of interest was amplified using the
0,3mM 50-GTCCCTGAGACTCTCCTGT and 50-CTGAGGA-
GACGGTGACC in 1X Pfx amplication buffer, 0,3mM dNTP
mix in a total volume of 50ml using 10ml cDNA and 1U
platinum Pfx DNA polymerase (Life Technologies, Carlsbad,
USA). The PCR was amplified with an initial denaturation at
948C for 5min, 40 cycles at 948C for 15 sec, 5 8C for 30 sec, and
688C for 60 sec.
Figure 1. Peripheral T follicular helper cells (pTFH) in ESRD patients and controls. (a) Gating strategy for CD4þCD45RACCR7þCXCR5þ pTFH. (b) PTFH
frequencies (percentage of CD4þ memory T cells) and pTFH concentrations (109/L) in ESRD patients and controls. Horizontal bars represent medians.
Bonferroni corrected.
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The PCR products were prepared for next-generation
sequencing on the Ion Torrent PGM using the Ion Express
Plus Fragment Library kit (Life Technologies). Ten to
twelves samples were sequenced simultaneously with the
400 bp technologies using the Ion PGM Template OT2 400
kit, Ion PGM Sequencing 400 Kit and Ion 314 Chip v2
according to the manufacturers recommendations. Data
were collected as FastQ files and converted to Fasta files. Data
were filtered and reads containing reliably VDJ-sequences
were selected using a cluster analysis (PMID:25556246). The
presence of V-segment and number of SHM in these reads
were determined using VDJsolver (PMID:17005006) [17].
Analysis of nucleotide mutations within the IgG
VH gene (SHM)
The method has been published in Barington et al. [18]:
reads were qualified by the presence of primer and MID
sequences and identical sequences (at least 1 forward and 1
reverse) were clustered. Clusters from the same PCR could
be identified based on the primers and MIDs and
were analyzed separately in the following: Clusters
were evaluated by a numerical programming algorithm
designed by the authors (details available from the
corresponding author). In brief, clusters were ordered
after declining number of members. The sequence of the
largest cluster was accepted if the cluster had an acceptable
balance of forward and reverse sequences. If not accepted,
the algorithm continued to the next cluster. Once a
sequence was accepted, it was compared with all smaller
clusters from the same PCR and these were discarded if
their sequence did not deviate by at least a certain number
of substitutions or insertions/deletions (indels) from the
index sequence. The number depended on the cluster sizes
and was selected to account for Taq-errors and other
common sequencing artefacts that allowed clonal sequen-
ces to diverge slightly. When all smaller clusters had been
dealt with, the process reiterated from the largest of the
remaining clusters and this process continued until all
clusters were either accepted or discarded. Rearrangements
passing the cluster evaluation were analyzed using
VDJsolver (http://www.cbs.dtu.dk/services/VDJsolver/) as
previously described [17] with the following modifications:
(i) improved identification of VH-genes by a Smith-
Waterman algorithm comparing with a database of VH
germline genes compiled from the international ImMuno-
GeneTics information system (IMGT) (http://www.imgt.
org) with omission of sequences unlikely to represent true
germline genes (level 5) as reported by Wang et al. [19] (ii)
improved sensitivity for D-genes by lowering the penalty
for inclusion of one D gene (iii) acceptance of two D-genes
in a rearrangement after accepting a penalty for two D
genes.
Statistical analysis
SPSS (version 11, Chicago, IL, USA) was used. Compar-
isons between multiple independent groups were per-
formed by the Kruskal–Wallis test, followed by the Mann–
Whitney U-test (two independent groups with continuous
values). In Figures 1 and 2(with multiple comparisons),
significant results were Bonferroni corrected. Comparisons
between two independent groups (binary values) were
performed with the Chi-square test. Paired analyses were
performed with the Wilcoxon signed rank test. Correla-
tions were performed with the Spearman’s rank test.
Values were presented as medians and minimum and
maximum values. A two-sided P-value< 0.05 was regarded
as significant.
As the number of unique IgG VH transcripts (each
representing a unique hypermutated B cell) showed
considerable interpersonal variation, we calculated the
SHM value ([number of mutated nucleotides/number of
investigated nucleotide positions within each unique IgG VH
transcript] 100) for each unique IgG VH transcript,
followed by the calculation of a median SHM value (ranging
over all unique IgG VH transcripts per participant) for each
control and ESRD patient and finally followed by group
comparison. A requirement for the determination of an
individual median SHM value was: a) unique 10 IgG VH
transcripts per personþ b) that each unique IgG VH
transcript contained >3 nucleotide mutations (in order to
account as hypermutated). The frequency of non-mutated
([number of unique IgG VH transcripts with 3 nucleotide
mutations per transcript/total number of unique IgG VH
transcripts per participant] 100), GC-derived, B cells was
Figure 2. Apoptosis in CXCR5þ pTFH and in CD4þ CXCR5 memory T
cells among ESRD patients and controls. Annexin V positivity in (CD4þ
CD45RA) CXCR5þ (pTFH) and (CD4þ CD45RA) CXCR5 memory T
cells derived from ESRD patients and controls. Horizontal bars represent
medians. Bonferroni corrected.
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calculated for each ESRD patient and control and followed
by group comparison.
Results
ESRD patients
ESRD (clinical data, Table 1) was secondary to hyperten-
sive nephropathy in five cases; type I diabetes in four cases;
polycystic renal disease in three cases; hydronephrosis in
three cases; and single instances of TTP, juvenile
nephronetosis, medullary sponge kidney, and nephroli-
thiasis. Compared with controls, the ESRD group was
characterized by elevated creatinine, blood urea nitrogen,
parathyroid hormone (PTH), and C-reactive protein
(CRP) levels but reduced albumin levels. ESRD patients
resembled controls with regard to leukocyte concentra-
tions apart from reduced B- and T-lymphocyte subset
concentrations and a tendency to reduced CD4þ/CD8þ
ratios, Table 1. The percentage of CD4þ CD45RA
(memory) T cells was increased in the ESRD group
(n¼ 19; 64.2% (of CD4þ T cells); 36.6–82.6%) compared
to the control group (n¼ 22; 42.3%; 20.5–76.1%),
P< 0.01, Table 1. A mean Kt/V value of 1.4 indicated
the clinical sufficiency of the dialysis regimen.
PTFH characteristics
Compared to controls (n¼ 22; 0.07 109/L; 0.01–
0.19 109/L), ESRD patients (n¼ 19; 0.03 109/L; 0.01–
0.08 109/L, P< 0.02, Bonferroni corrected) were charac-
terized by reduced absolute numbers of pTFH (Fig. 1). PTFH
frequencies (% of CD4þ memory T cells) also differed
between controls (n¼ 22; 14.9%; 6.7–63.6%) and ESRD
patients (n¼ 19; 11.6%; 3.4–17.2%, P< 0.02, Bonferroni
corrected) (Fig. 1). Compared to those of controls (n¼ 21;
79D MFI; 45–165D MFI), pTFH, from ESRD patients,
tended toward diminished CXCR5 positivity (n¼ 19; 64D
MFI; 13–112D MFI, P¼ 0.12, data not shown).
Annexin V and the CXCR5þ/dichotomy
A signature of the ESRD group (n¼ 9; median: 25.7%;
16.8–34.0%, P¼ 0.04, Bonferroni corrected) was increased
frequencies of pTFH positive for the apoptosis marker
annexin V [20] (controls: n¼ 10; 15.9%; 2.4–32.6%)
(Fig. 2). Frequencies of CD4þ CD45RA CXCR5 memory
T cells, positive for annexin V, did not discriminate between
ESRD patients (n¼ 9; 32.4%; 23.9–50.2%, P¼ 0.33) and
controls (n¼ 10; 28.9%; 3.5–48.9%) (Fig. 2). For both ESRD
patients and controls, CXCR5þ pTFH were less apoptotic
than CD4þ CXCR5 memory T cells (P< 0.04, Bonferroni
corrected), (Fig. 2). Judged by forward-side scatter
characteristics [21], annexin Vþ cells, from both ESRD
patients and controls, were not dead.
CXCL-13 in ESRD patients and controls
CXCL13 levels were elevated in ESRD (n¼ 19; 90 pg/ml;
55–800 pg/ml, P< 0.01) versus controls (n¼ 18; 62 pg/ml;
42–134 pg/ml) (Fig. 3). CXCL13 levels in ESRD, censored for
clinical autoimmunity (n¼ 14; 87 pg/ml; 55–243 pg/ml,
P¼ 0.01), also differed from controls (data not shown).
CXCL13 levels among ESRD secondary to clinical autoim-
munity (four type I diabetes and one TTP) (n¼ 5; 90 pg/ml;
70–800 pg/ml) did not differ from ESRD patients without
clinical autoimmunity, P¼ 0.85 (data not shown). In the
ESRD group, CXCL13 levels did not discriminate between
pre- (n¼ 11; 63 pg/ml; 44–106 pg/ml, P¼ 0.86, data not
shown) and (immediate) post-dialysis (n¼ 11; 70 pg/ml;
39–254 pg/ml), but pre- and (immediate) post-dialysis levels
correlated (Spearman, n¼ 11, r¼ 0.61, P<0.05).
SHM
The degree of nucleotide mutation within the IgG VH region
(comprising the important antigen-binding domains:
complementary determining region ([CDR] 1 and 2) did
not discriminate between ESRD patients (n¼ 10; 7.4%;
5.8–8.8%, P¼ 0.21) and controls (n¼ 10; 8.4%; 5.8–9.5%)
(Fig. 4). Frequencies of non-mutated (expressing unique IgG
VH transcripts with 3 nucleotide mutations per tran-
script), GC-derived, B cells did not differ significantly
between ESRD patients (n¼ 10; 6.5%; 2.0–18.8%, P¼ 0.36)
and controls (n¼ 10; 4.5%; 1.4–14.0%) (Fig. 4).
Figure 3. Serum CXCL13 levels in ESRD and healthy controls. Serum
CXCL13 concentrations in the ESRD and control group. Horizontal bars
represent medians.
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Discussion
This is the first study documenting that ESRD (also
without a history of clinical auto-immunity) is associated
with elevated serum CXCL13 levels (exceeding healthy
control CXCL13 levels nearly 1.5 times). This ratio was
verified by comparing additional 20 ESRD patients and 20
controls (clinical and para-clinical data not shown),
showing the CXCL13 levels in ESRD to be elevated 1.6
times, P< 0.01. Of relevance for the CXCL13 elevations in
ESRD is the fact that HD dependency is associated with a
substantial increase in circulating endotoxin levels com-
pared both to non-dialysis-dependent chronic kidney
disease (NDD-CKD) and to healthy controls [22]. As
human B cells, monocytes, macrophages, and dendritic
cells respond to endotoxins with increased CXCL13
production [23–25], the elevated circulating CXCL13
levels in ESRD patients likely reflects endotoxin induced
immune activation. That especially physiological changes,
related to HD (i.e., increased gastrointestinal endotoxin
release due to the fluid translocations occurring in the
post-dialysis period [22]), may give rise to elevated CXCL-
13 levels was indicated by our observation, that CXCL13
concentrations, in 17 patients with (advanced) NDD-CKD,
did not differ significantly from those of controls but were
significantly reduced compared to those of the ESRD
group (data not shown). Like ESRD, NDD-CKD is known
to be associated with increased gut permeability to
endotoxins [26]. The lack of elevated CXCL13 levels in
NDD-CKD patients is interesting, since NDD-CKD
patients exhibit superior vaccine responses compared to
HD dependent ESRD patients [27].
As a low molecular weight protein (approximately
10 kDa), CXCL-13, like CXCL8 (IL-8) [28], should be
dialyzable. The dissociation constant Kd, between CXCL13
and its receptor complex CXCR5/Epstein–Barr virus-
induced receptor 2 (EBI2), is 1.49 107M [29]. This Kd
value is more than 20-fold higher than circulating pre-
dialysis CXCL-13 concentrations. Within the context of
ESRD, the majority of CXCR5 receptors are therefore
supposed to be free, suggesting a rapid turnover of CXCL13
in ESRD, consistent with the rather short half-lives
(minutes) of circulating cytokines in general [28]. Increased
endotoxin exposure has not been observed during HD
therapy [22], suggesting that the HD procedure per se was
not the cause for the unchanged CXCL-13 levels (immedi-
ate) post-dialysis. Instead, the lack of difference and the
correlation between pre- and immediate post-dialysis
CXCL13 levels suggest, in combination with indications of
rapid CXCL13 turnover and CXCL13 dialyzability, a
substantial and continuous de novo CXCL-13 production
in ESRD, largely unaffected by the HD procedure itself. The
elevated CXCL13 levels, in ESRD, can be viewed as an
appropriate response to the immunological danger sig-
nals [30] constituted by the increased gut mediated
endotoxin release, since CXCL13, through positive auto-
feedback, controls lymphoid neo-genesis [31] and hence
prepares the humoral immune system to deal with potential
microbial threats. Elevated CXCL13 levels induce internali-
zation of CXCR5 [32] consistent with the tendency toward
decreased CXCR5 expression in ESRD pTFH. It needs to be
emphasized, that CXCL13-induced CXCR5 internalization,
within the GC, is a tightly regulated and localized
process [32]. Hence, dysregulated CXCL13 production,
within the GC of the ESRD patient, could perturb the
dynamics of GC residing CXCR5þ B and T lymphocytes
consistent with the antibody dysregulation observed in
conditions with elevated CXCL13 production as well as
internalization of CXCR5 [33, 34].
The moderately elevated CXCL13 levels, characterizing
the ESRD group, were consistent with the general absence of
patients with active autoimmunity within this group.
Though upregulation of CXCL13 was implicated in the
development of autoimmune insulitis in mice [35], we
observed no difference in serum CXCL13 levels between
ESRD patients with (primarily IDDM) and without a history
of clinical autoimmunity. Opposite the pronounced
CXCL13 elevations (elevated six times relative to controls)
encountered in active SLE [12] and active rheumatoid
arthritis [36], the long clinical history with type I diabetes,
characterizing our IDDM ESRD patients (data not shown),
was consistent with extinguished insulitis [37]. This could
explain the lack of more pronounced CXCL13 elevations in
these ESRD patients.
Reduced frequencies and concentrations of CCR7þ
CXCR5þ pTFH were features of ESRD. Although CXCR5þ
CCR7low PD-1high pTFH are mentioned as a subset of
Figure 4. Minor differences in somatic hypermutation (SHM) between
ESRD and controls. Somatic hypermutation (SHM)within the IgG VH gene
(comprising the antigen-binding domains CDR1 and CDR2) and
frequencies of non-mutated (expressing unique IgG VH transcripts
with 3 nucleotide mutations per IgG VH transcript), GC-derived, B cells
in ESRD patients and controls. Horizontal bars represent medians.
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efficient antibody inducing blood TFH [9], previous, [8, 38],
as well as a recent, reports [39] have emphasized that the
phenotypic profile CCR7þCXCR5þ is sufficient to delineate
true pTFH capable of helping na€ve B cells. Frequencies of
CD4þ CD45RA (memory) T cells were increased in the
ESRD compared to the control group, consistent with
previous reports [40] and with the pro-inflammatory state of
ESRD [41]. Consequently, measured as percentage of CD4þ
T cells, pTFH frequencies were not reduced in the ESRD
group relative to controls. However, after vaccinating
controls with alum-conjugated vaccines, we observed
CCR7þ CXCR5þ pTFH to be the most expanded CD4þ
memory T cell subset (data not shown). Among the
inflammatory cytokines induced by alum-conjugated vac-
cines are IL-1b and IL-18 [42]. Interestingly, IL-18 levels are
also increased secondary to ESRD [43]. Taking the increased
IL-18 levels and the increased infectious burden of ESRD
patients into account, suggest that the reduced pTFH
frequencies, among antigen experienced ESRD CD4 mem-
ory T cells, reflect compromised pTFH generation and/or
survival.
ESRD pTFHwere more apoptotic than control pTFH, but
pTFH, in general, were less apoptotic than their CD4þ
CXCR5 memory T cell counterparts consistent with the
basal inertness of pTFH [8] and consonant with an anti-
apoptotic effect mediated by CXCR5 [44, 45]. Hence, due to
increased CXCR5 internalization, ESRD pTFH may be
engendered more susceptible to the generalized lymphocyte
stress encountered in ESRD [46], resulting in selective pTFH
apoptosis and death.
Our protocol did not allow for vaccination. In another
context, however, we observed, as previously reported [9],
pTFH expansion, 1-week post-vaccination, in three out of
four vaccine responders (not ESRD patients; data not
shown). These dynamics contrasted with reduced (pre-
vaccination) pTFH frequencies and delayed (>1-week
post-vaccination) pTFH expansion in a poor vaccine
responder with a humoral immunodeficiency (data not
shown). Collectively, these data support an association
between pTFH and vaccination dynamics and suggest a
clinical importance of diminished pTFH frequencies in
ESRD. The observation that HIV patients, with a
peripheral CD4þ CXCR5þ count 60 106/L, responded
significantly less to diphtheria toxoid, at week 24 [47], also
indicated a role for the much reduced pTFH concen-
trations (median: 30 106/L) in contributing to the
attenuated vaccination dynamics in ESRD [48]. However,
pTFH are important not only for vaccination responses but
also for the dynamics of antibody recall responses in
general [16]. Hence, decreased pTFH levels, increased
pTFH apoptosis, and potentially disturbed GC migration
(due to dysregulated CXCL13 secretion and reduced
CXCR5 surface expression) collectively point to slower
antibody dynamics as underlying the compromised
humoral immunity in ESRD.
SHM is a process which ensures additional antibody
diversity and provides the basis for the subsequent
selection of high-affinity antibodies (affinity maturation).
SHM correlates with the neutralizing potential of anti-
bodies [49] as well as infectious susceptibility [50]. We
used primers specific for IgG in order to determine SHM
in circulating isotype switched IgGþ memory B cells, that
is, B cells which had been implicated in GC reactions.
Long-lasting high-affinity antibody responses to protein
antigens (such as hepatitis B and influenza) rely heavily
upon GC reactions [51]. Circulating, GC-derived, IgGþ
memory B cells have, also in elderly individuals, a rapid
turnover. Assessed by deuterated glucose, the circulating
isotype switched memory B cell subset displayed a
disappearance rate (half-life) of around 13 days [52]. As
our ESRD patients had minimum 6 months of HD
dependence, we feel confident that the SHM data, obtained
from the ESRD patients, pertained to their state of ESRD.
Determination of the degree of nucleotide mutation,
within the antigen-binding domains (comprising CDR 1
and CDR 2) of the IgG VH domain, demonstrated that
ESRD is not accompanied by markedly reduced GC-
specific SHM (approximately 10%, compared to controls)
nor by an increased frequency of non-mutated GC-derived
B cells. Hence, our data suggest that GC-derived anti-
bodies/B cells, generated in the context of ESRD, have
(largely and homogeneously) retained their diversity and
hence the basis for the selection of high-affinity antibodies
through the process of affinity maturation. This suggests
preserved neutralizing potential of the antibodies them-
selves, although the ability of phagocytes to opsonize may
be compromised in ESRD [53]. Importantly, it also
provides a rationale for pursuing vaccination of ESRD
patients [54] as their attenuated vaccine responses, as
indicated by our data, result from altered GC dynamics
and not from structural antibody deficiencies. Although
SHM does not provide information on antibody dynamics
and was only slightly reduced in the ESRD group, the
tendency toward SHM reduction in the ESRD group was
consonant with the reduced pTFH frequencies. This relates
to the importance of the follicular counterparts of pTFH
for the reiterative process of SHM within the GC [55].
As pTFH differentiation both mirror the development of
their follicular counterparts [9] and as pTFH, upon
antigen reencounter, home back into the GC, in order to
differentiate into their follicular cousins [9], the reduced
pTFH levels were in fact consistent with a tendency toward
reduced SHM in ESRD. In conclusion, ESRD is character-
ized by elevated circulating levels of the GC-derived
chemokine CXCL13, reduced frequencies and concentra-
tions of pTFH, pronounced pTFH apoptosis but largely
K. Assing et al. Germinal center-related parameters in ESRD
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intact GC-specific SHM. Collectively, these findings
suggest that a component of the antibody deficiency, in
ESRD, is primarily due to disturbed GC dynamics rather
than antibody quality per se.
Acknowledgments
We are grateful for the technical work performed by Ingrid
Qualman.
Authors' Contributions
Kristian Assing designed the study and collected material.
Christian Nielsen performed flow-cytometric analyses.
Marianne Jakobsen and Knud Vejen performed PCR
work. Alexander Scholze provided serum samples from
patients with non-dialysis-dependent chronic kidney dis-
ease. Mads Nybo performed biochemical analyses. Grete
Soerensen organized patients on hemodialysis. Sussie
Mortensen performed next-generation sequencing. Torben
Baringto: performed bioinformatic analysis of next-genera-
tion sequencing data. Claus Bistrup designed the study.
Kristian Assing wrote the paper and rest of the authors
critically reviewed the manuscript.
Conflict of Interest
The results presented in this paper have not been published
previously, in whole, part or in abstract format. The authors
declare no financial support or relationships that might pose
a conflict of interest. Tables or figures have not been
reproduced from other sources.
References
1. Stevens, C. E., H. J. Alter, P. E. Taylor, E. A. Zang, E. J. Harley,
and W. Szmuness. 1984. Hepatitis B vaccine in patients
receiving hemodialysis. Immunogenicity and efficacy. N.
Engl. J. Med. 311(8):496–501.
2. Girndt, M., M. Pietsch, and H. Kohler. 1995. Tetanus immuni-
zation and its association to hepatitis B vaccination in patients
with chronic renal failure. Am. J. Kidney. Dis. 26(3):454–460.
3. Vogtlander, N. P., A. Brown, R. M. Valentijn, G. F.
Rimmelzwaan, and A. D. Osterhaus. 2004. Impaired response
rates, but satisfying protection rates to influenza vaccination
in dialysis patients. Vaccine 22(17–18):2199–2201.
4. Schulman, S. L., A. Deforest, B. A. Kaiser, M. S. Polinsky, and
H. J. Baluarte. 1992. Response to measles-mumps-rubella
vaccine in childrenondialysis. Pediatr.Nephrol. 6(2):187–189.
5. Slinin, Y., R. N. Foley, and A. J. Collins. 2006. Clinical
epidemiology of pneumonia in hemodialysis patients: the
USRDS waves 1, 3, and 4 study. Kidney Int. 70(6):1135–1141.
6. Berman, S. J., E. W. Johnson, C. Nakatsu, M. Alkan, R. Chen,
and J. LeDuc. 2004. Burden of infection in patients with end-
stage renal disease requiring long-term dialysis. Clin. Infect.
Dis. 39(12):1747–1753.
7. Pallikkuth, S., A. Parmigiani, S. Y. Silva, V. K. George, M.
Fischl, R. Pahwa, and S. Pahwa. 2012. Impaired peripheral
blood T-follicular helper cell function in HIV-infected
nonresponders to the 2009 H1N1/09 vaccine. Blood 120(5):
985–993.
8. Chevalier, N., D. Jarrossay, E. Ho, D. T. Avery, C. S. Ma, D.
Yu, F. Sallusto, S. G. Tangye, and C. R. Mackay. 2011. CXCR5
expressing human central memory CD4 T cells and
their relevance for humoral immune responses. J. Immunol.
186(10):5556–5568.
9. He, J., L. M. Tsai, Y. A. Leong, X. Hu, C. S. Ma, N. Chevalier,
X. Sun, K. Vandenberg, S. Rockman, Y. Ding, L. Zhu,W.Wei,
C.Wang, A. Karnowski, G. T. Belz, J. R. Ghali, M. C. Cook, D.
S. Riminton, A. Veillette, P. L. Schwartzberg, F. Mackay, R.
Brink, S. G. Tangye, C. G. Vinuesa, C. R.Mackay, Z. Li, andD.
Yu. 2013. Circulating precursor CCR7(lo)PD-1(hi) CXCR5
(þ) CD4(þ) T cells indicate Tfh cell activity and promote
antibody responses upon antigen reexposure. Immunity
39(4):770–781.
10. Leon, B., A. Ballesteros-Tato, J. L. Browning, R. Dunn, T. D.
Randall, and F. E. Lund. 2012. Regulation of T(H)2
development by CXCR5þ dendritic cells and lymphotoxin-
expressing B cells. Nat. Immunol. 13(7):681–690.
11. Widney, D. P., E. C. Breen, W. J. Boscardin, S. G. Kitchen, J.
M. Alcantar, J. B. Smith, J. A. Zack, R. Detels, and O.
Martinez-Maza. 2005. Serum levels of the homeostatic B cell
chemokine, CXCL13, are elevated during HIV infection. J.
Interferon Cytokine Res. 25(11):702–706.
12. Schiffer, L., P. Kumpers, A. M. Davalos-Misslitz, M. Haubitz,
H. Haller, H. J. Anders, T. Witte, and M. Schiffer. 2009. B-
cell-attracting chemokine CXCL13 as a marker of disease
activity and renal involvement in systemic lupus erythema-
tosus (SLE). Nephrol. Dial. Transplant. 24(12):3708–3712.
13. Pahl, M. V., S. Gollapudi, L. Sepassi, P. Gollapudi, R.
Elahimehr, and N. D. Vaziri. 2010. Effect of end-stage renal
disease on B-lymphocyte subpopulations, IL-7, BAFF and
BAFF receptor expression. Nephrol. Dial. Transplant. 25(1):
205–212.
14. Schejbel, L., H. Marquart, V. Andersen, H. Permin, P.
Andersen, A. Svejgaard, and T. Barington. 2005. Deficiency of
somatic hypermutation of immunoglobulin G transcripts is a
better predictor of severe respiratory tract infections than lack
of memory B cells in common variable immunodeficiency. J.
Clin. Immunol. 25(4):392–403.
15. Odegard, V. H., and D. G. Schatz. 2006. Targeting of somatic
hypermutation. Nat. Rev. Immunol. 6(8):573–583.
16. Vinuesa, C. G., S. G. Tangye, B. Moser, and C. R. Mackay.
2005. Follicular B helper T cells in antibody responses and
autoimmunity. Nat. Rev. Immunol. 5(11):853–865.
Germinal center-related parameters in ESRD K. Assing et al.
232 © 2016 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd.
17. Ohm-Laursen, L., M. Nielsen, S. R. Larsen, and T. Barington.
2006. No evidence for the use of DIR, D-D fusions,
chromosome 15 open reading frames or VH replacement
in the peripheral repertoire was found on application of an
improved algorithm, JointML, to 6329 human immunoglob-
ulin H rearrangements. Immunology 119(2):265–277.
18. Hansen, T. O., A. B. Lange, and T. Barington. 2015. Sterile
DJH rearrangements reveal that distance between gene
segments on the human Ig H chain locus influences their
ability to rearrange. J. Immunol. 194(3):973–982.
19. Wang, Y., K. J. Jackson, B. Gaeta, W. Pomat, P. Siba, W. A.
Sewell, and A. M. Collins. 2011. Genomic screening by 454
pyrosequencing identifies a new human IGHV gene and
sixteen other new IGHV allelic variants. Immunogenetics
63(5):259–265.
20. Koopman, G., C. P. Reutelingsperger, G. A. Kuijten, R. M.
Keehnen, S. T. Pals, andM. H. van Oers. 1994. Annexin V for
flow cytometric detection of phosphatidylserine expression
on B cells undergoing apoptosis. Blood 84(5):1415–1420.
21. Lizard, G. 2001. Changes in light scatter properties are a
general feature of cell death but are not characteristic of
apoptotically dying cells. Cytometry 46(1):65–66.
22. McIntyre, C. W., L. E. Harrison, M. T. Eldehni, H. J. Jefferies,
C. C. Szeto, S. G. John,M. K. Sigrist, J. O. Burton, D. Hothi, S.
Korsheed, P. J. Owen, K. B. Lai, and P. K. Li. 2011. Circulating
endotoxemia: a novel factor in systemic inflammation and
cardiovascular disease in chronic kidney disease. Clin. J. Am.
Soc. Nephrol. 6(1):133–141.
23. Litsiou, E., M. Semitekolou, I. E. Galani, I. Morianos, A.
Tsoutsa, P. Kara, D. Rontogianni, I. Bellenis, M. Konstanti-
nou, K. Potaris, E. Andreakos, P. Sideras, S. Zakynthinos, and
M. Tsoumakidou. 2013. CXCL13 production in B cells via
toll-like receptor/lymphotoxin receptor signaling is involved
in lymphoid neogenesis in chronic obstructive pulmonary
disease. Am. J. Respir. Crit. Care. Med. 187(11)1194–1202.
24. Carlsen, H. S., E. S. Baekkevold, H. C. Morton, G. Haraldsen,
and P. Brandtzaeg. 2004. Monocyte-like and mature macro-
phages produce CXCL13 (B cell-attracting chemokine 1)
in inflammatory lesions with lymphoid neogenesis. Blood
104(10):3021–3027.
25. Perrier, P., F. O.Martinez, M. Locati, G Bianchi, MNebuloni,
G Vago, F Bazzoni, S Sozzani, P Allavena, and A. Mantovani.
2004. Distinct transcriptional programs activated by inter-
leukin-10 with or without lipopolysaccharide in dendritic
cells: induction of the B cell-activating chemokine, CXC
chemokine ligand 13. J. Immunol. 172(11):7031–7042.
26. Vaziri, N. D. 2012. CKD impairs barrier function and alters
microbial flora of the intestine: a major link to inflammation
and uremic toxicity. Curr. Opin. Nephrol. Hypertens. 21(6):
587–592.
27. Grzegorzewska, A. E. 2012. Hepatitis B vaccination in chronic
kidney disease: review of evidence in non-dialyzed patients.
Hepat. Mon. 12(11):e7359.
28. Tarakcioglu, M., A. B. Erbagci, C. Usalan, R. Deveci, and R.
Kocabas. 2003. Acute effect of hemodialysis on serum levels of
the proinflammatory cytokines. Mediators Inflamm. 12(1):
15–19.
29. Barroso, R., M. L. Martinez, S. Barrondo, B. Vega, B. L.
Holgado, P. Lucas, A. Baillo, J. Salles, J. M. Rodriguez-Frade,
and M. Mellado. 2012. EBI2 regulates CXCL13-mediated
responses by heterodimerization with CXCR5. FASEB. J.
26(12):4841–4854.
30. Pradeu, T., and E. L. Cooper. 2012. The danger theory: 20
years later. Front Immunol. 3:287.
31. Ansel, K.M., V. N. Ngo, P. L. Hyman, S. A. Luther, R. Forster,
J. D. Sedgwick, J. L. Browning,M. Lipp, and J. G. Cyster. 2000.
A chemokine-driven positive feedback loop organizes
lymphoid follicles. Nature 406(6793):309–314.
32. Figge, M. T., A. Garin, M. Gunzer, M. Kosco-Vilbois, K. M.
Toellner, andM.Meyer-Hermann. 2008. Deriving a germinal
center lymphocyte migrationmodel from two-photon data. J.
Exp. Med. 205(13):3019–3029.
33. Cagigi, A., F. Mowafi, L. V. Phuong Dang, K. Tenner-Racz, A.
Atlas, S. Grutzmeier, P. Racz, F. Chiodi, and A. Nilsson. 2008.
Altered expression of the receptor-ligand pair CXCR5/
CXCL13 in B cells during chronic HIV-1 infection. Blood
112(12):4401–4410.
34. Boswell, K. L., R. Paris, E. Boritz, D. Ambrozak, T.
Yamamoto, S. Darko, K. Wloka, A. Wheatley, S. Narpala, A.
McDermott, M. Roederer, R. Haubrich, M. Connors, J. Ake,
D. C. Douek, J. Kim, C. Petrovas, and R. A. Koup. 2014.
Loss of circulating CD4 T cells with B cell helper function
during chronic HIV infection. PLoS Pathog. 10(1):
e1003853.
35. Astorri, E., M. Bombardieri, S. Gabba, M. Peakman, P.
Pozzilli, and C. Pitzalis. 2010. Evolution of ectopic lymphoid
neogenesis and in situ autoantibody production in auto-
immune nonobese diabetic mice: cellular and molecular
characterization of tertiary lymphoid structures in pancreatic
islets. J. Immunol. 185(6):3359–3368.
36. Rioja, I., F. J. Hughes, C. H. Sharp, L. C. Warnock, D. S.
Montgomery, M. Akil, A. G. Wilson, M. H. Binks, and M. C.
Dickson. 2008. Potential novel biomarkers of disease activity
in rheumatoid arthritis patients: CXCL13, CCL23, trans-
forming growth factor alpha, tumor necrosis factor receptor
superfamily member 9, and macrophage colony-stimulating
factor. Arthritis Rheum. 58(8):2257–2267.
37. In’t, V. P. 2011. Insulitis in human type 1 diabetes: the quest
for an elusive lesion. Islets 3(4):131–138.
38. Morita, R., N. Schmitt, S. E. Bentebibel, R. Ranganathan, L.
Bourdery, G. Zurawski, E. Foucat, M. Dullaers, S. Oh, N.
Sabzghabaei, E. M. Lavecchio, M. Punaro, V. Pascual, J.
Banchereau, and H. Ueno. 2011. Human blood CXCR5(þ)
CD4(þ) T cells are counterparts of T follicular cells and
contain specific subsets that differentially support antibody
secretion. Immunity 34(1):108–121.
K. Assing et al. Germinal center-related parameters in ESRD
© 2016 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd. 233
39. Ueno, H., J. Banchereau, and C. G. Vinuesa. 2015.
Pathophysiology of T follicular helper cells in humans and
mice. Nat. Immunol. 16(2):142–152.
40. Betjes, M. G, A. W. Langerak, A. van der Spek, E. A. de Wit,
and N. H. Litjens. 2011. Premature aging of circulating T cells
in patients with end-stage renal disease. Kidney Int. 80(2):
208–217.
41. Carrero, J. J., and P. Stenvinkel. 2010. Inflammation in end-
stage renal disease—what have we learned in 10 years? Semin.
Dial. 23(5):498–509.
42. Li, H., S. Nookala, and F. Re. 2007. Aluminum hydroxide
adjuvants activate caspase-1 and induce IL-1beta and IL-18
release. J. Immunol. 178(8):5271–5276.
43. Porazko, T., J. Kuzniar, M. Kusztal, T. J. Kuzniar, W. Weyde,
M. Kuriata-Kordek, andM. Klinger. 2009. IL-18 is involved in
vascular injury in end-stage renal disease patients. Nephrol.
Dial. Transplant. 24(2):589–596.
44. Burkle, A., M. Niedermeier, A. Schmitt-Graff, W. G. Wierda,
M. J. Keating, and J. A. Burger. 2007. Overexpression of the
CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell
chronic lymphocytic leukemia. Blood 110(9):3316–3325.
45. Qiuping, Z., X. Jie, J. Youxin,W.Qun, J.Wei, L. Chun,W. Jin,
L. Yan, H. Chunsong, Y. Mingzhen, G. Qingping, L. Qun, Z.
Kejian, S. Zhimin, L. Junyan, and T. Jinquan. 2005. Selectively
frequent expression of CXCR5 enhances resistance to
apoptosis in CD8(þ)CD34(þ) T cells from patients with
T-cell-lineage acute lymphocytic leukemia. Oncogene 24(4):
573–584.
46. Pernice, F., F. Floccari, L. Nostro, C. Caccamo, N. Belghity, S.
Mantuano, A. Romeo, A. Barilla’, C. Aloisi, A. Ruello, N.
Frisina, andM. Buemi. 2006. Oxidative stress, sister chromatid
exchanges and apoptosis in the pathogenesis of lymphocyto-
penia in ESRD patients. J. Nephrol. 19(5):613–620.
47. Rabian, C., I. Tschope, P. Lesprit, C. Katlama, J. M. Molina, J.
L. Meynard, J. F. Delfraissy, G. Chene, and Y. Levy. 2010.
Cellular CD4 T cell responses to the diphtheria-derived
carrier protein of conjugated pneumococcal vaccine and
antibody response to pneumococcal vaccination in HIV-
infected adults. Clin. Infect. Dis. 50(8):1174–1183.
48. Litjens, N. H., M. Huisman, M. van den Dorpel, and M. G.
Betjes. 2008. Impaired immune responses and antigen-
specific memory CD4þ T cells in hemodialysis patients. J.
Am. Soc. Nephrol. 19(8):1483–1490.
49. Sok, D., U. Laserson, J. Laserson, Y. Liu, F Vigneault, J. P.
Julien, B. Briney, A. Ramos, K. F. Saye, K. Le, A Mahan, S.
Wang, M. Kardar, G. Yaari, L. M.Walker, B. B. Simen, E. P. St
John, P. Y. Chan-Hui, K. Swiderek, S. H. Kleinstein, G. Alter,
M. S. Seaman, A. K. Chakraborty, D. Koller, I. A. Wilson, G.
M. Church, D. R. Burton, and P. Poignard. 2013. The effects
of somatic hypermutation on neutralization and binding in
the PGT 121 family of broadly neutralizing HIV antibodies.
PLoS Pathog. 9(11):e1003754.
50. Andersen, P., H. Permin, V. Andersen, L. Schejbel, P. Garred,
A. Svejgaard, and T. Barington. 2005. Deficiency of somatic
hypermutation of the antibody light chain is associated with
increased frequency of severe respiratory tract infection in
common variable immunodeficiency. Blood 105(2):511–517.
51. Folb, P. I., E. Bernatowska, R. Chen, J. Clemens, A. N. Dodoo,
S. S. Ellenberg, C. P. Farrington, T. J. John, P. H. Lambert, N.
E. Macdonald, E. Miller, D. Salisbury, H. J. Schmitt, C. A.
Siegrist, and O. Wimalaratne. 2004. A global perspective on
vaccine safety and public health: the Global Advisory
Committee on Vaccine Safety. Am. J. Public. Health 94(11):
1926–1931.
52. Macallan, D. C., D. L. Wallace, Y. Zhang, H. Ghattas, B.
Asquith, L. C. de, A. Worth, G. Panayiotakopoulos, G. E.
Griffin, D. F. Tough, and P. C. Beverley. 2005. B-cell kinetics
in humans: rapid turnover of peripheral blood memory cells.
Blood 105(9):3633–3640.
53. Vanholder, R., L. A. Van, A. M. Dhondt, S. R. De, and S.
Ringoir. 1996. Influence of uraemia and haemodialysis on
host defence and infection. Nephrol. Dial. Transplant. 11(4):
593–598.
54. Kotton, C. N. 2011. Vaccinations in kidney transplant
patients: searching for optimal protection. Clin. J. Am. Soc.
Nephrol. 6(9):2099–2101.
55. De Silva, N. S., and U. Klein. 2015. Dynamics of B cells in
germinal centres. Nat. Rev. Immunol. 15(3):137–148.
Germinal center-related parameters in ESRD K. Assing et al.
234 © 2016 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd.
